- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04588519
tAN to Mitigate Withdrawal Behaviors in Neonates
December 7, 2022 updated by: Spark Biomedical, Inc.
Transcutaneous Auricular Neurostimulation (tAN) to Mitigate Withdrawal Behaviors in Neonates With Opioid Withdrawal
This first in-human-neonates, open-label pilot trial is designed to determine whether use of tAN in newborns with NOWS receiving oral morphine allows for faster weaning of morphine and decrease morphine use altogether.
Reducing Neonatal Opioid Withdrawal Syndrome (NOWS) symptoms may also help lessen or eliminate the need for opioid medication and shorten the length of the hospital stay.
The neurostimulation device, currently called the Roo is a safe form of neurostimulation that uses sticker-like patches worn in and around the ear during the withdrawal period.
The patches deliver a small and painless current of electrical pulses to the skin and underlying cranial nerves.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This first in-human-neonates, open-label pilot trial is designed to determine whether use of tAN in newborns with NOWS receiving oral morphine allows for faster weaning of morphine and decrease morphine use altogether.
After obtaining parental consent, tAN is delivered to the left ear in NOWS newborns who are on a stable morphine dose for >12h (control dose), using a disposable, multi-channel (Channel1: auricular branch of the vagus nerve (ABVN); Channel2: ATN) earpiece electrode (Spark Biomedical, Inc).
30-minutes of tAN is delivered one hour prior to scheduled morphine dose, up to four times daily for up to 12 days.
The device is programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2
milliamps (mA); channel 2: 100 Hz, mean intensity 0.6±0.2
mA.
Nurses score the Finnegan Neonatal Abstinence Scoring Tool (FNAST) every 3h after feeding and morphine is weaned every 12h if FNAST scores <8.
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 months to 1 year (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Neonates or infants with opioid withdrawal or Neonatal Abstinence Syndrome (NAS) who have withdrawal scores requiring morphine replacement therapy. They must be clinically stable, on minimal respiratory support (Continuous positive airway pressure (CPAP), nasal cannula, or room air), >33 weeks gestational age at enrollment, and currently receiving replacement therapy for opioid dependence.
- Stable neonates who are dependent on opioids, such as after extracorporeal membrane oxygenation, severe illness or brain injury, will be included in this study, as these neonates represent a population in which tAN could minimize withdrawal while not adding to burden of pharmacotherapies. Congenital syndromes may be included if the infants do not have major, unrepaired anomalies.
Exclusion Criteria:
- Unstable infants or those requiring significant respiratory support.
- Repeated episodes of autonomic instability (apnea or bradycardia) which are not self-resolving *
- Infants <33weeks gestation at enrollment.
- Major unrepaired congenital anomalies
- Cardiomyopathy *Preterm infants commonly have short periods of shallow or absent breathing or lower heart rate termed apnea and bradycardia, respectively, and most are being treated for these physiologic manifestations of prematurity with caffeine, an effective central stimulant. Infants are on cardiorespiratory monitors through the nursery stay with recording devices to capture events and play them back. However, nearly all of these events are self resolving, meaning the infant resolves the breathing pause or bradycardia on their own. Infants who require repeated episodes of stimulation to come out of these events are defined as unstable. Similarly, infants on significant respiratory support are not stable, and will not be eligible.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active Transcutaneous Auricular Neurostimulation
Transcutaneous Auricular Neurostimulation programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2
mA; channel 2: 100 Hz, mean intensity 0.6±0.2
mA
|
Spark Roo tAN System programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2
mA; channel 2: 100 Hz, mean intensity 0.6±0.2
mA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With no Adverse Events Related to Bradycardia (HR < 80 Bpm), Worsening of Swallowing or Feeding, Skin Irritation, or Elevation of Neonatal Infant Pain Scores.
Time Frame: 12 days
|
No adverse events of bradycardia (HR < 80 bpm), worsening of swallowing or feeding, skin irritation, or elevation of Neonatal Infant Pain Scores.
|
12 days
|
Mean Finnegan Scores During Days of tAN Sessions
Time Frame: 12 days
|
The Finnegan Scale assesses 31 of the most common signs of neonatal drug withdrawal syndrome and is scored on the basis of pathological significance and severity of the adverse symptoms.
Scores for each sign are added to obtain a total score.
Total scores range from 0-20, where lower scores are indicative of less severe signs of neonatal drug withdrawal symptoms.
|
12 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Morphine Weaning
Time Frame: 12 days
|
Defined as the number of days between tAN therapy initiation and morphine discontinuation.
A shorter duration of morphine weaning indicates better treatment efficacy.
|
12 days
|
Length of Hospital Stay
Time Frame: From participant birth to hospital discharge, a median of 17 days
|
Defined as the number of days between birth and discharge.
A shorter length of stay indicates better treatment efficacy.
|
From participant birth to hospital discharge, a median of 17 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 30, 2020
Primary Completion (Actual)
December 1, 2020
Study Completion (Actual)
December 30, 2020
Study Registration Dates
First Submitted
October 8, 2020
First Submitted That Met QC Criteria
October 8, 2020
First Posted (Actual)
October 19, 2020
Study Record Updates
Last Update Posted (Estimate)
December 28, 2022
Last Update Submitted That Met QC Criteria
December 7, 2022
Last Verified
December 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00090960
- 1R43DA050360-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
No plan to share participant data
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Abstinence Syndrome
-
Indiana UniversityCompletedNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal Syndrome | Neonatal Opioid WithdrawalUnited States
-
Milton S. Hershey Medical CenterNational Institute on Drug Abuse (NIDA)RecruitingNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal SyndromeUnited States
-
Spark Biomedical, Inc.Medical University of South Carolina; University of Texas Southwestern Medical...RecruitingNeonatal Abstinence Syndrome | Neonatal Opioid Withdrawal SyndromeUnited States
-
Thomas Jefferson UniversityChiesi Farmaceutici S.p.A.CompletedNeonatal Abstinence Syndrome | Neonatal Opiate Withdrawal SyndromeUnited States
-
PediatrixCompletedNeonatal Abstinence Syndrome | Neonatal Withdrawal SyndromeUnited States
-
Tufts Medical CenterCompletedNeonatal Abstinence Syndrome | Neonatal Opioid WithdrawalUnited States
-
Tulane UniversityRecruitingNeonatal Abstinence Syndrome | Substance Withdrawal, NeonatalUnited States
-
University of VermontNational Institute on Drug Abuse (NIDA); Johns Hopkins University; University... and other collaboratorsCompletedOpioid-use Disorder | Neonatal Abstinence Syndrome | Opioid Withdrawal | Neonatal Opioid Withdrawal SyndromeUnited States
-
University of AlbertaAlberta Health services; Alberta Innovates Health Solutions; Covenant HealthRecruitingNeonatal Abstinence SyndromeCanada
-
University Hospital, CaenRecruitingNeonatal Abstinence SyndromeFrance
Clinical Trials on Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System
-
Spark Biomedical, Inc.CompletedOpioid-use Disorder | Opioid WithdrawalUnited States
-
University of Texas Southwestern Medical CenterNot yet recruitingPain, Postoperative | Opioid Use | Lumbar Spine InjuryUnited States